Cadrenal Therapeutics (NASDAQ: CVKD) has announced the appointment of Lee Scott Golden, MD, to its board of directors (BOD) as an independent director, effective immediately.
Dr. Golden currently serves as EVP and CMO at PTC Therapeutics (Nasdaq: PTCT), where he leads global clinical development across a broad rare disease pipeline. He also serves as chairman of the advisory board for closely held Coagulation Sciences. Dr. Golden brings more than 25 years of industry experience to the role, with increasing responsibilities, managing global, cross-functional teams responsible for creating and deploying strategic and clinical development plans. He has extensive experience across multiple therapeutic areas and with orphan diseases.
In a statement, Quang X. Pham, chairman and CEO of Cadrenal, commented, “We are delighted to welcome Dr. Golden to our Board. Lee’s deep experience in late-stage clinical development, particularly in cardiovascular medicine and anticoagulation, is highly aligned with our mission to deliver safer, more predictable anticoagulant options for patients with significant unmet needs. His track record in guiding therapies through clinical development and regulatory pathways will be invaluable as we continue to advance tecarfarin and our broader pipeline.”
Dr. Golden remarked, “Cadrenal Therapeutics is working in an area of high clinical importance, where better anticoagulation options could meaningfully impact outcomes for patients with complex cardiovascular conditions. I look forward to working with the Board and the leadership team to help guide the company’s strategy and clinical programs as we seek to bring differentiated therapies to patients and create value for shareholders.”
